Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

NextCure, Inc. Common Stock (NXTC)

Pharmaceutical Preparations

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include NC410 a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1, NC762 a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or B7-H4, a protein expressed on multiple tumor types, and NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or AML, blast cells, and leukemic stem cells, or LSCs.

9000 VIRGINIA MANOR ROAD, SUITE 200
BELTSVILLE, MD

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/09/2019

Market Cap

41,681,144

Shares Outstanding

27,900,000

Weighted SO

27,903,027

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

CTMX --.--%

SPRO --.--%

NLTX --.--%

TIL --.--%

ASMB --.--%

NUVB --.--%

ACHL --.--%

Beta

0.6710

Last Div

0.0000

Range

0.98-2.57

Chg

-0.0701

Avg Vol

64890

Mkt Cap

41681144

Exch

NASDAQ

Country

US

Phone

240-399-4900

DCF Diff

1.3273

DCF

0.2327

Div Yield

0.0000

P/S

6.6329

EV Multiple

-0.4480

P/FV

0.4878

Div Yield %

0.0000

P/E

-0.6801

PEG

-0.0680

Payout

0.0000

Current Ratio

8.3499

Quick Ratio

8.3499

Cash Ratio

1.9245

DSO

34.8504

DIO

0.0000

Op Cycle

34.8504

DPO

543.0592

CCC

-508.2088

Gross Margin

0.4572

Op Margin

-10.1311

Pretax Margin

-9.7516

Net Margin

-9.7516

Eff Tax Rate

-0.0466

ROA

-0.5973

ROE

-0.5763

ROCE

-0.6938

NI/EBT

1.0000

EBT/EBIT

0.9625

EBIT/Rev

-10.1311

Debt Ratio

0.0600

D/E

0.0721

LT Debt/Cap

0.0614

Total Debt/Cap

0.0672

Int Coverage

-65.2964

CF/Debt

-7.4424

Equity Multi

1.2007

Rec Turnover

10.4733

Pay Turnover

0.6721

Inv Turnover

0.0000

FA Turnover

0.6125

Asset Turnover

0.0613

OCF/Share

-1.6384

FCF/Share

-1.6609

Cash/Share

3.0900

OCF/Sales

-7.2931

FCF/OCF

1.0137

CF Coverage

-7.4424

ST Coverage

-80.6866

CapEx Coverage

-72.7460

Div&CapEx Cov

-72.7460

P/BV

0.4878

P/B

0.4878

P/S

6.6329

P/E

-0.6801

P/FCF

-0.8971

P/OCF

-0.9094

P/CF

-0.9094

PEG

-0.0680

P/S

6.6329

EV Multiple

-0.4480

P/FV

0.4878

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Dec 25, 09:55 Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing Zacks Investment Research Dec 25, 09:55 Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing Zacks Investment Research Dec 25, 09:55 Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing GlobeNewswire Inc. Dec 14, 06:45 NextCure Provides Year-End Clinical Pipeline Updates

Revenue Product Segmentation